Shanghai Siyanli

The brand that outlasted its buyer

Twenty-nine years of continuous operation in China’s premium lifestyle-beauty segment is unusual enough. What makes Shanghai Siyanli 思妍丽 (“beauty through elegance”) genuinely distinctive is what those years contained: three institutional shareholders, four ownership configurations, two existential crises, and one deal that walked away — leaving a brand stronger than the acquirer that once turned it down.

Siyanli operates 163 stores and 19 medical-aesthetics clinics across 48 Chinese cities, earning RMB 849 million in 2024 with a profit of RMB 81 million. Beauty Farm Medical Health (2373.HK), which acquired 100% of the company in October 2025 for RMB 1.25 billion, described the transaction as its 三强聚合 (top-three consolidation) strategy — uniting the first, second, and third-largest beauty-services brands in China under a single platform. Siyanli is the third name in that sequence, the one that had already survived a failed acquisition attempt before the consolidation buyer arrived.

The story of how it got there is a case study in what institutional-grade brand management actually means when the ownership structure underneath a company changes, twice, without warning.

Décléor, Thailand, and a decade-early bet

The brand began in 1996 at Beijing’s Shidu Department Store, built around a French distributor partnership with Décléor and a Thai-design SPA aesthetic that had no domestic category to occupy. China’s lifestyle-beauty market did not yet exist as a recognizable consumer segment. The original operator — identified only as “Mr. Zhang” (张先生) in Siyanli’s 2016 twentieth-anniversary coverage — had imported a service concept that would take Chinese consumers another decade to recognize and seek out in large numbers.

The Shanghai store opened at Jinjiang Dickson in 1998. Franchising launched in 1999. Through the next decade, Siyanli built its network in premium department-store slots — the 院线 (institutional-channel) positioning that would become its most durable competitive advantage. When competitors later entered China’s beauty-services market, they competed on price in mass channels. Siyanli competed on address.

The 院线 tier is not a marketing claim; it is a supply-chain and real-estate discipline. Stores occupy first-floor or mezzanine positions in first- and new-first-tier city malls — the same neighbourhoods as luxury-goods retailers. Lease economics are expensive. The clientele is narrow. More than 90% of Siyanli’s revenue has consistently come from top-20 Chinese cities. This is a deliberate constraint that creates an equally deliberate distance from mass-channel competitors. In China’s beauty-services market, where brands from CHLITINA to smaller regional chains have competed on franchise affordability and geographic spread, Siyanli made itself expensive to copy and uncomfortable to compete with directly.

The Shanghai entity was formally incorporated on 31 December 2009 at 100 Fahua Town Road, Changning District — the current headquarters address. The same year, the company established the Siyanli Vocational Beauty School to systematize training and raise the service floor across its growing franchise network. In 2008, the company had already integrated RF, IPL, and ultrasound devices into its treatment protocols — a technical upgrade that competitors could not replicate cheaply and that reinforced the 院线 claim for the next decade.

Two in-house product investments followed. In 2011, the first BIOYAYA outpatient medical-aesthetics clinic opened in Shanghai — a full decade before the segment reached mainstream investor attention. In 2012, Siyanli launched DR.Bio, a laboratory-grade skincare line developed in partnership with a Korean growth-factor and polypeptide research laboratory. Both moves signaled the same institutional posture: build capabilities early, at a cost level that creates a durable distance from competitors who enter the category later.

The deal that almost changed everything

The Caohongji chapter began in 2017. Zhuosheng Investment acquired a 26% stake for RMB 392 million; that stake was subsequently transferred to listed Caohongji at a fraction of the original cost — a structural irregularity that foreshadowed the regulatory problems ahead. In March 2018, Caohongji announced a RMB 1.295 billion acquisition of the remaining 74%, which would have made Siyanli a wholly-owned A-share listed subsidiary.

The plan looked coherent on the surface. Siyanli had the track record. The beauty-services segment was growing. The 794.57% asset-revaluation premium on Siyanli’s net assets prompted an immediate inquiry letter from the Shenzhen Stock Exchange — a standard regulatory flag in China’s 2018 acquisition environment — but these things had been navigated before. The company reorganized its performance commitments: cumulative net profit of RMB 1.0 to 1.6 billion over 2018 to 2021, no margin for error. The board was reconfigured. Cash-flow plans were locked.

The real complication arrived on 28 December 2018. MBK Partners signed a separate agreement to acquire 23.53% of Siyanli directly from existing shareholders — six days before Caohongji withdrew its CSRC application. Two buyers now held competing stakes in a company whose entire operational strategy had been premised on one of them prevailing. When Caohongji formally terminated the acquisition on 1 July 2019, Siyanli was free. MBK Partners was already inside the cap table.

Consider what a deal collapse of this kind costs a company that was not just a passive acquisition target. Siyanli had reorganized its governance, its performance commitments, and its capital allocation around an A-share listing thesis that no longer existed. The cumulative profit targets — RMB 1.0 to 1.6 billion over four years — were not aspirational benchmarks; they were deal conditions that had structured how management made operating decisions. Releasing that structure is not purely liberating. It requires a company to rebuild its sense of what it is for, on whose terms, and toward what future owner. That process took until October 2020 to complete.

In December 2019, China’s State Administration for Market Regulation (SAMR) fined MBK Partners RMB 350,000 for failing to file its 23.53% acquisition under Anti-Monopoly Law joint-control concentration rules. MBK absorbed the penalty. Siyanli was unaffected operationally — but the antitrust episode underlined how unusual the transaction structure had been.

Then, in 2022, Shanghai went into a COVID lockdown. Siyanli’s stores in its home market — where it held its densest network — were closed for approximately ten weeks. Full-year revenue was RMB 565 million; post-tax loss was RMB 36.4 million. It was the only loss year in the brand’s disclosed financial history. The operational infrastructure that management had built over three decades — the franchise systems, the training academy, the BIOYAYA medical-aesthetics platform — absorbed the blow and held.

The medical-aesthetics engine

What made Siyanli acquisition-worthy in October 2025 was not primarily the 163 lifestyle-beauty stores. It was BIOYAYA.

The first BIOYAYA outpatient clinic had opened in Shanghai in 2011, a decade before China’s medical-aesthetics boom became a mainstream institutional investment thesis. The clinic operated as a licensed medical institution offering botulinum toxin treatments, growth-factor therapies, and energy-device procedures in a regulated clinical environment — a margin structure fundamentally different from the lifestyle-beauty segment. BIOYAYA generated 50 to 60 percent gross margin against the roughly 30 percent typical of a Siyanli lifestyle store. By the time Beauty Farm acquired the company, the BIOYAYA network had grown to 19 clinics.

The significance of building BIOYAYA when Siyanli did is not merely timing. In China’s medical-aesthetics segment, the regulatory licensing requirements — outpatient medical institution qualification, qualified medical staff, prescribed facility standards — create a structural barrier that consumer-beauty brands cannot cross without organizational investment they rarely make. Siyanli made the investment in 2011, before the category attracted capital at scale. By 2025, the brand had eleven years of operating experience in a licensed clinical environment that later-entering competitors were still acquiring at significant cost. When Beauty Farm’s analysts explained the acquisition rationale, the BIOYAYA platform appeared alongside the membership base as one of two non-replicable assets.

In parallel, Siyanli had built a small portfolio of distributed international brands: THALGO (France, 2015), DELAROM (France, 2018), and WELLKIN (Korea, 2020). French and Korean formulations positioned at the same premium-tier customer as its service model — distributed through the existing store network, adding product-margin revenue to a service-heavy P&L.

The October 2020 LBO consolidation by MBK Partners and Standard Chartered completed the ownership cleanup. Caohongji’s residual 26% was acquired for RMB 474.5 million. SYL Holding (74%) and Shanghai Anyan (26%) held a clean cap table; the company was valued at approximately USD 224 million. For the first time since 2017, Siyanli had institutional sponsors whose only purpose was to build value for a strategic exit — not to use the brand as a vehicle for their own A-share listing objectives.

The revenue recovery confirmed the bet. In 2023, revenue jumped 44.7% to RMB 818 million with a post-tax profit of RMB 69.4 million — the sharpest single-year recovery in the brand’s disclosed history. In July 2023, Shanghai’s Commerce Commission designated Siyanli as a Multinational Regional Headquarters (37th batch) — a credential that recognized the company’s international brand distribution infrastructure and its role as a regional management hub. In 2024, Frost & Sullivan certified Siyanli as the #3 beauty-services brand in China by revenue, at RMB 849 million and RMB 81 million profit.

Consolidation and what comes next

The headline figures of the 2025 acquisition invite a direct comparison with Caohongji’s 2018 bid. Caohongji offered RMB 1.295 billion for 74% of Siyanli — implying a full-company value of approximately RMB 1.75 billion — and walked away. Beauty Farm paid RMB 1.25 billion for 100% of a company seven years older, with a cleaner cap table, a proven BIOYAYA platform, and a Frost & Sullivan top-three ranking. The lower headline figure obscured a superior strategic outcome in every respect that a consolidator cares about.

Beauty Farm structured the deal 67% in cash (RMB 836 million) and 33% in shares (15.798 million Beauty Farm shares at HKD 28.71 per share). No earn-out, no performance conditions, no regulatory questions about asset revaluation premiums. The independent appraiser, Jinzheng, assessed Siyanli’s goodwill at RMB 1.395 billion — more than the total consideration, a reflection of the intangible value in membership, brand positioning, and the BIOYAYA clinical network.

The 60,000 active Siyanli members — who represent approximately 44% of the combined Beauty Farm Group’s membership base post-acquisition — will be onboarded into a digital middle platform that Beauty Farm’s chairman and CEO have described in investor interviews as a 38-system, ten-year, RMB 100 million-plus build. The combined group has guided for RMB 4 billion in revenue and over RMB 500 million in adjusted net profit by 2026, having also acquired NARUIER 奈瑞儿 (the #2 beauty-services brand) earlier in 2024.

Siyanli enters the Beauty Farm platform as the premium flagship — the brand with the longest operating history, the densest urban network, and a medical-aesthetics sub-brand that the parent company’s own analysts described as the structural rationale for the acquisition. The brand that survived an A-share takeover collapse, a pandemic loss year, and two PE holding periods did not emerge diminished. It emerged with a cleaner balance sheet, a validated clinical model, and a parent company building the largest beauty-services platform in China.

Last updated: May 12, 2026